S&P 500   3,128.31 (-3.02%)
DOW   27,081.16 (-3.15%)
QQQ   215.45 (-2.68%)
AAPL   288.25 (-3.33%)
FB   196.98 (-1.86%)
MSFT   168.07 (-1.65%)
AMZN   1,972.67 (-1.82%)
NVDA   261.60 (-4.27%)
BABA   206.00 (-0.08%)
MU   52.09 (-5.31%)
GE   11.33 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.36 (-1.81%)
S&P 500   3,128.31 (-3.02%)
DOW   27,081.16 (-3.15%)
QQQ   215.45 (-2.68%)
AAPL   288.25 (-3.33%)
FB   196.98 (-1.86%)
MSFT   168.07 (-1.65%)
AMZN   1,972.67 (-1.82%)
NVDA   261.60 (-4.27%)
BABA   206.00 (-0.08%)
MU   52.09 (-5.31%)
GE   11.33 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.36 (-1.81%)
S&P 500   3,128.31 (-3.02%)
DOW   27,081.16 (-3.15%)
QQQ   215.45 (-2.68%)
AAPL   288.25 (-3.33%)
FB   196.98 (-1.86%)
MSFT   168.07 (-1.65%)
AMZN   1,972.67 (-1.82%)
NVDA   261.60 (-4.27%)
BABA   206.00 (-0.08%)
MU   52.09 (-5.31%)
GE   11.33 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.36 (-1.81%)
S&P 500   3,128.31 (-3.02%)
DOW   27,081.16 (-3.15%)
QQQ   215.45 (-2.68%)
AAPL   288.25 (-3.33%)
FB   196.98 (-1.86%)
MSFT   168.07 (-1.65%)
AMZN   1,972.67 (-1.82%)
NVDA   261.60 (-4.27%)
BABA   206.00 (-0.08%)
MU   52.09 (-5.31%)
GE   11.33 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.36 (-1.81%)
Log in

NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

$18.07
-1.19 (-6.18 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$17.98
Now: $18.07
$19.60
50-Day Range
$17.56
MA: $19.48
$21.36
52-Week Range
$3.52
Now: $18.07
$21.93
Volume221,055 shs
Average Volume1.69 million shs
Market Capitalization$2.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-744-2487

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$1.32 per share

Profitability

Net Income$-64,120,000.00
Net Margins-19,483.96%

Miscellaneous

Employees39
Market Cap$2.02 billion
Next Earnings Date3/17/2020 (Estimated)
OptionableOptionable

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.


Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

What price target have analysts set for AUPH?

8 Wall Street analysts have issued 12-month price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $11.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $22.29 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

News coverage about AUPH stock has been trending very negative on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aurinia Pharmaceuticals.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 5,830,000 shares, an increase of 6.0% from the January 15th total of 5,500,000 shares. Based on an average trading volume of 3,420,000 shares, the short-interest ratio is currently 1.7 days. Currently, 7.0% of the company's stock are short sold. View Aurinia Pharmaceuticals' Current Options Chain.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Micron Technology (MU), Array Biopharma (ARRY), Exelixis (EXEL), Novavax (NVAX), Corbus Pharmaceuticals (CRBP) and Synergy Pharmaceuticals (SGYP).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (7.18%), Point72 Asset Management L.P. (3.22%), Franklin Resources Inc. (1.19%), Perceptive Advisors LLC (0.64%), Goldman Sachs Group Inc. (0.56%) and Renaissance Technologies LLC (0.52%).

Which major investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Franklin Resources Inc., Victory Capital Management Inc., SG Americas Securities LLC, Patriot Financial Group Insurance Agency LLC, Bank of Montreal Can, Ironwood Investment Management LLC and ProShare Advisors LLC.

Which major investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Perceptive Advisors LLC, Renaissance Technologies LLC, Ikarian Capital LLC, Broadfin Capital LLC, Crawford Lake Capital Management LLC and Schonfeld Strategic Advisors LLC.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $18.04.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $2.02 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]


MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  491 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  805
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel